Sign In
Buy DVAX
$15.50
+0 (+0%)
At Close: May 08, 2026
Dynavax Responds to Deep Track and Highlights Long-Term Value Creation Strategy
04:52pm, Wednesday, 19'th Feb 2025
Reiterates Meaningful Board Change Already Underway EMERYVILLE, Calif. , Feb. 19, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage
Exclusive: Investor Deep Track launches proxy fight at Dynavax, nominates 4 directors
08:04am, Wednesday, 19'th Feb 2025
Life sciences investment firm Deep Track Capital is launching a board fight at Dynavax Technologies , pressing for new directors to prioritize the development of the company's hepatitis B vaccine inst
Goldman Sachs Turns Bearish On Vaccine Maker Dynavax Amid Shingles And Hepatitis B Uncertainty
03:11pm, Tuesday, 11'th Feb 2025
Goldman Sachs downgraded Dynavax Technologies Corporation DVAX reflecting updated views and recent competitive dynamics for vaccines.
Dynavax to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on February 20, 2025
05:42pm, Thursday, 06'th Feb 2025
EMERYVILLE, Calif. , Feb. 6, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will
Wall Street Analysts Believe Dynavax Technologies (DVAX) Could Rally 93.2%: Here's is How to Trade
10:55am, Wednesday, 29'th Jan 2025
The mean of analysts' price targets for Dynavax Technologies (DVAX) points to a 93.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement a
Dynavax Advances Board Refreshment Program
06:00am, Monday, 27'th Jan 2025
Appoints Emilio Emini and Lauren Silvernail to Board of Directors; Two Directors to Step Down at 2025 Annual Meeting Intends to Seek Stockholder Approval for Declassification of Board at 2025 Annual M
Dynavax Technologies (DVAX) Upgraded to Buy: Here's What You Should Know
01:00pm, Thursday, 16'th Jan 2025
Dynavax Technologies (DVAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Highlights
09:00am, Monday, 13'th Jan 2025
Preliminary 2024 HEPLISAV-B® net product revenue grew 26% year-over-year to approximately $268 million Enrollment completed in Phase 1/2 shingles trial; top line results expected in Q3 2025 New $30 m
Does Dynavax Technologies (DVAX) Have the Potential to Rally 93.52% as Wall Street Analysts Expect?
11:00am, Wednesday, 27'th Nov 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 93.5% in Dynavax Technologies (DVAX). While the effectiveness of this highly sought-after metric is questionabl
Dynavax to Present at the 7th Annual Evercore HealthCONx Conference
04:05pm, Tuesday, 26'th Nov 2024
EMERYVILLE, Calif. , Nov. 26, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, to
Dynavax Technologies: What The Stock Buyback Means. What It Doesn't
06:36pm, Wednesday, 13'th Nov 2024
Today, we revisit Dynavax Technologies Corporation, whose shares have moved up nicely after the company announced a significant buyback authorization. In addition, DVAX's flagship product Heplisav-B c
Dynavax Technologies (DVAX) Upgraded to Buy: Here's Why
01:00pm, Monday, 11'th Nov 2024
Dynavax Technologies (DVAX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Predict an 88.32% Upside in Dynavax Technologies (DVAX): Here's What You Should Know
11:00am, Monday, 11'th Nov 2024
The consensus price target hints at an 88.3% upside potential for Dynavax Technologies (DVAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earn
Dynavax Announces $100 Million Accelerated Share Repurchase Program
08:00am, Monday, 11'th Nov 2024
EMERYVILLE, Calif. , Nov. 11, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, to
Dynavax Technologies (DVAX) Q3 Earnings Surpass Estimates
06:30pm, Thursday, 07'th Nov 2024
Dynavax Technologies (DVAX) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.10 per share a year ago.
